An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents
Nemours Children's Clinic · NCT06147973
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 14–19 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 148
- US sites recruiting
- 1
- Study start
- February 14, 2024
- Record last updated
- July 20, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to learn about cardiovascular disease risk among adolescent girls with overweight/obesity. The main questions this trial aims to answer are:
- Does an acceptance-based healthy lifestyle intervention demonstrate more weight loss than a health education intervention?
- Does an acceptance-based healthy lifestyle intervention show more improvements in participants' physiological, health-related, and psychological factors compared to a health education intervention?
Participants in this trial will
- Engage in treatment for 6-months, comprising of a mixture of in-person and remote group sessions, occurring at Drexel University or over a video-conferencing platform.
- Complete various assessments. These include self-reported questionnaires, measures of weight, height, body composition, blood pressure, and blood lipids, and wearing of smart watches to measure sleep and physical activity.
Researchers will compare the acceptance-based and health education intervention groups to see if the acceptance-based treatment will indeed be effective in improving participants' health outcomes.
Being studied: Acceptance-based Treatment (ABT); Health Education (HE) Comparison
Conditions: Overweight and Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Ages 14-19
- Gender identification as girl
- BMI percentile ≥ 85th percentile for sex-and-age
Exclusion Criteria
- Experience of weight loss of ≥5% of body weight in the past 6 months for any reason except post-partum weight loss
- Having recently begun or changed the dosage of any medication known to affect appetite or body composition within the last 3 months
- Plans to move out of the area within the next year
- Active cancer or cancer requiring treatment in the past 2 years (except non-melanoma skin cancer)
- Active or chronic infections (e.g., HIV or TB)
- Active cardiovascular disease or event including hospitalization or therapeutic procedures for treatment of heart disease in the past 6 months
- Active kidney disease
- History of bariatric surgery
- Lung disease: chronic obstructive airway disease requiring use of oxygen (e.g., emphysema or chronic bronchitis)
- Diagnosed diabetes (type 1 or 2)
- Any condition prohibiting physical activity
- Diagnosis of an eating disorder
- Have a mental handicap or are currently experiencing other severe psychopathology that would limit their ability to engage in the treatment program (e.g., severe depression, active psychotic disorder)
- Recent or ongoing problem with drug abuse, alcohol abuse, or addiction
- Currently pregnant or less than 3 months post-partum
- Anticipation of a possible pregnancy in the next year
- Unwillingness to report possible or confirmed pregnancies promptly during the course of the trial
Recruiting US locations
Drexel University
Philadelphia, PA 19104
Site contact: Stephanie Manasse, PhD · 2155537157 · smm522@drexel.edu
Study contacts (from the official record)
- Stephanie Manasse, PhD · 215-553-7157 · smm522@drexel.edu
Similar studies in Pennsylvania
All weight loss studies in Pennsylvania →- RecruitingHealthy volunteersPhase 1
Pharmacogenetics of Response to GLP1R Agonists
University of Maryland, Baltimore
- Location
- Lancaster, PA
- Eligibility basics
- Ages 18–89
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Philadelphia, PA + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Beaver, PA + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- West Chester, PA + 43 other US sites
- Eligibility basics
- Ages 18+